{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:46:58Z","timestamp":1791942418969,"version":"4.3.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Next-generation sequencing (NGS) is standard practice in metastatic pancreatic ductal adenocarcinoma (PDAC), yet its prognostic utility in patients undergoing curative-intent resection remains poorly defined. Characterizing whether driver mutations independently influence post-surgical outcomes [overall survival (OS), time-to-recurrence (TTR), and pathological response (PR)] may inform perioperative risk stratification and patient selection for emerging targeted therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a retrospective cohort study of adults undergoing pancreatectomy for PDAC at a single high-volume academic center (2016\u20132025), with concurrent NGS profiling. Clinicopathologic and genomic data (\n                      <jats:italic>KRAS<\/jats:italic>\n                      ,\n                      <jats:italic>TP53<\/jats:italic>\n                      ,\n                      <jats:italic>CDKN2A<\/jats:italic>\n                      ,\n                      <jats:italic>SMAD4<\/jats:italic>\n                      , and\n                      <jats:italic>BRCA2<\/jats:italic>\n                      mutations) were obtained from an integrated institutional data commons. OS and TTR were evaluated using Kaplan\u2013Meier analysis and multivariable Cox proportional hazards regression. PR (College of American Pathologists grade 0\u20131) was assessed using logistic regression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 188 eligible patients (median age: 66; 42.5% female), 83.5% received neoadjuvant chemotherapy and 12.8% achieved major pathological response.\n                      <jats:italic>KRAS<\/jats:italic>\n                      was the most prevalent mutation (84.6%), followed by\n                      <jats:italic>TP53<\/jats:italic>\n                      (61.7%),\n                      <jats:italic>CDKN2A<\/jats:italic>\n                      (33.0%),\n                      <jats:italic>SMAD4<\/jats:italic>\n                      (18.1%), and\n                      <jats:italic>BRCA2<\/jats:italic>\n                      (3.2%). Median TTR and OS were 10.8 and 27.1\u00a0months, respectively. In multivariable analysis,\n                      <jats:italic>TP53<\/jats:italic>\n                      mutation was associated with shorter OS (HR, 1.65 95% CI 1.02\u20132.66), and\n                      <jats:italic>CDKN2A<\/jats:italic>\n                      mutation with shorter TTR (HR 1.69, 95% CI 1.19\u20132.39).\n                      <jats:italic>KRAS<\/jats:italic>\n                      was associated with poorer PR compared to wild type (OR 4.45, 95% CI 1.26\u201315.65).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      In this exploratory analysis,\n                      <jats:italic>TP53<\/jats:italic>\n                      and\n                      <jats:italic>CDKN2A<\/jats:italic>\n                      mutations were independently associated with poorer outcomes post-PDAC resection, supporting the potential of upfront NGS for perioperative risk stratification. Prospective, multicenter validation is needed to establish clinical utility.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12094-026-04564-6","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:17:28Z","timestamp":1791940648000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Driver mutation profiling by next-generation sequencing predicts survival and recurrence after curative-intent resection for pancreatic ductal adenocarcinoma: a genomic cohort study"],"prefix":"10.1007","author":[{"given":"Muhammad Maisam","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaniala K.","family":"Aragon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin A.","family":"Cher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaleem S.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clayton T.","family":"Marcinak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra W.","family":"Acher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Kratz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed","family":"Murtaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Burkard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3843-9687","authenticated-orcid":false,"given":"Syed Nabeel","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"issue":"9","key":"4564_CR1","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jama.2021.13027","volume":"326","author":"W Park","year":"2021","unstructured":"Park W, Chawla A, O\u2019Reilly EM. Pancreatic cancer: a review. JAMA. 2021;326(9):851\u201362. https:\/\/doi.org\/10.1001\/jama.2021.13027.","journal-title":"JAMA"},{"issue":"9","key":"4564_CR2","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1158\/1078-0432.CCR-15-0426","volume":"21","author":"LA Chantrill","year":"2015","unstructured":"Chantrill LA, Nagrial AM, Watson C, et al. Precision medicine for advanced pancreas cancer: the individualized molecular pancreatic cancer therapy (IMPaCT) trial. Clin Cancer Res. 2015;21(9):2029\u201337. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0426.","journal-title":"Clin Cancer Res"},{"issue":"13","key":"4564_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16132329","volume":"16","author":"V Cortiana","year":"2024","unstructured":"Cortiana V, Abbas RH, Chorya H, et al. Personalized medicine in pancreatic cancer: the promise of biomarkers and molecular targeting with Dr Michael J Pishvaian. Cancers (Basel). 2024;16(13):2329. https:\/\/doi.org\/10.3390\/cancers16132329.","journal-title":"Cancers (Basel)"},{"issue":"27","key":"4564_CR4","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1200\/JCO.20.01364","volume":"38","author":"DPS Sohal","year":"2020","unstructured":"Sohal DPS, Kennedy EB, Cinar P, et al. Metastatic pancreatic cancer: ASCO guideline update. J Clin Oncol. 2020;38(27):3217\u201330. https:\/\/doi.org\/10.1200\/JCO.20.01364.","journal-title":"J Clin Oncol"},{"issue":"7592","key":"4564_CR5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature16965","volume":"531","author":"P Bailey","year":"2016","unstructured":"Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531(7592):47\u201352. https:\/\/doi.org\/10.1038\/nature16965.","journal-title":"Nature"},{"key":"4564_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00505-0","volume":"8","author":"A Yousef","year":"2024","unstructured":"Yousef A, Yousef M, Chowdhury S, et al. Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. NPJ Precis Oncol. 2024;8:27. https:\/\/doi.org\/10.1038\/s41698-024-00505-0.","journal-title":"NPJ Precis Oncol"},{"issue":"4","key":"4564_CR7","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1097\/SLA.0000000000006794","volume":"282","author":"BA Campbell","year":"2025","unstructured":"Campbell BA, Solinas D, Blackford AL, et al. Mutational status of driver genes in resected pancreatic ductal adenocarcinoma is associated with pathological characteristics and overall survival. Ann Surg. 2025;282(4):525\u201333. https:\/\/doi.org\/10.1097\/SLA.0000000000006794.","journal-title":"Ann Surg"},{"issue":"17","key":"4564_CR8","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1002\/cncr.33038","volume":"126","author":"CA McIntyre","year":"2020","unstructured":"McIntyre CA, Lawrence SA, Richards AL, et al. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma. Cancer. 2020;126(17):3939\u201349. https:\/\/doi.org\/10.1002\/cncr.33038.","journal-title":"Cancer"},{"issue":"3","key":"4564_CR9","doi-asserted-by":"publisher","first-page":"e173420","DOI":"10.1001\/jamaoncol.2017.3420","volume":"4","author":"ZR Qian","year":"2018","unstructured":"Qian ZR, Rubinson DA, Nowak JA, et al. Association of alterations in main driver genes with outcomes of patients with resected pancreatic ductal adenocarcinoma. JAMA Oncol. 2018;4(3):e173420. https:\/\/doi.org\/10.1001\/jamaoncol.2017.3420.","journal-title":"JAMA Oncol"},{"issue":"7624","key":"4564_CR10","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","volume":"335","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, et al. The STROBE statement: guidelines for reporting observational studies. BMJ. 2007;335(7624):806\u20138. https:\/\/doi.org\/10.1136\/bmj.39335.541782.AD.","journal-title":"BMJ"},{"key":"4564_CR11","doi-asserted-by":"publisher","DOI":"10.1200\/CCI-24-00265","author":"KS Ahmed","year":"2025","unstructured":"Ahmed KS, Marcinak CT, Ali MM, et al. A novel electronic health record\u2013based data commons for pancreatic cancer. JCO Clin Cancer Inform. 2025. https:\/\/doi.org\/10.1200\/CCI-24-00265.","journal-title":"JCO Clin Cancer Inform"},{"key":"4564_CR12","volume-title":"Protocol for the examination of specimens from patients with carcinoma of the pancreas","author":"LJ Burgart","year":"2021","unstructured":"Burgart LJ, Chopp W, Jain D. Protocol for the examination of specimens from patients with carcinoma of the pancreas. College of American Pathologists; 2021."},{"issue":"1","key":"4564_CR13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41379-020-00683-9","volume":"34","author":"BV Janssen","year":"2021","unstructured":"Janssen BV, Tutucu F, van Roessel S, et al. Amsterdam international consensus meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy. Mod Pathol. 2021;34(1):4\u201312. https:\/\/doi.org\/10.1038\/s41379-020-00683-9.","journal-title":"Mod Pathol"},{"issue":"11","key":"4564_CR14","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/s41575-021-00486-6","volume":"18","author":"X Chen","year":"2021","unstructured":"Chen X, Zeh HJ, Kang R, et al. Cell death in pancreatic cancer: from pathogenesis to therapy. Nat Rev Gastroenterol Hepatol. 2021;18(11):804\u201323. https:\/\/doi.org\/10.1038\/s41575-021-00486-6.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"4564_CR15","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241290482","volume":"16","author":"MK Kim","year":"2024","unstructured":"Kim MK, Cho IR, Kim Y, et al. Prognostic value of the TP53 mutation in patients with pancreatic ductal adenocarcinoma receiving FOLFIRINOX. Ther Adv Med Oncol. 2024;16:17588359241290482. https:\/\/doi.org\/10.1177\/17588359241290482.","journal-title":"Ther Adv Med Oncol"},{"key":"4564_CR16","doi-asserted-by":"publisher","unstructured":"Maddalena M, Mallel G, Nataraj NB, et al. TP53 missense mutations in pancreatic ductal adenocarcinoma are associated with enhanced fibrosis and an immunosuppressive microenvironment. Proc Natl Acad Sci U S A. 2021;118(23):e2025631118. https:\/\/doi.org\/10.1073\/pnas.2025631118.","DOI":"10.1073\/pnas.2025631118"},{"issue":"3","key":"4564_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/biom9030087","volume":"9","author":"R Fontana","year":"2019","unstructured":"Fontana R, Ranieri M, La Mantia G, et al. Dual role of the alternative reading frame ARF protein in cancer. Biomolecules. 2019;9(3):87. https:\/\/doi.org\/10.3390\/biom9030087.","journal-title":"Biomolecules"},{"issue":"13","key":"4564_CR18","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1158\/0008-5472.CAN-14-0734","volume":"74","author":"AM Lennon","year":"2014","unstructured":"Lennon AM, Wolfgang CL, Canto MI, et al. Early detection of pancreatic cancer: what will it take to diagnose and treat curable pancreatic neoplasia? Cancer Res. 2014;74(13):3381\u20139. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-0734.","journal-title":"Cancer Res"},{"issue":"2","key":"4564_CR19","doi-asserted-by":"publisher","DOI":"10.1172\/JCI175369","volume":"134","author":"MT Dillon","year":"2024","unstructured":"Dillon MT, Guevara J, Mohammed K, et al. Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation. J Clin Invest. 2024;134(2):e175369. https:\/\/doi.org\/10.1172\/JCI175369.","journal-title":"J Clin Invest"},{"issue":"29","key":"4564_CR20","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1200\/JCO.19.00730","volume":"37","author":"KC Cuneo","year":"2019","unstructured":"Cuneo KC, Morgan MA, Sahai V, et al. Dose escalation trial of the Wee1 inhibitor adavosertib with gemcitabine and radiation in locally advanced pancreatic cancer. J Clin Oncol. 2019;37(29):2643\u201350. https:\/\/doi.org\/10.1200\/JCO.19.00730.","journal-title":"J Clin Oncol"},{"key":"4564_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.19.00124","volume":"3","author":"T Al Baghdadi","year":"2019","unstructured":"Al Baghdadi T, Halabi S, Garrett-Mayer E, et al. Palbociclib in pancreatic and biliary cancers with CDKN2A alterations: results from the Tapur Study. JCO Precis Oncol. 2019;3:1\u20138. https:\/\/doi.org\/10.1200\/PO.19.00124.","journal-title":"JCO Precis Oncol"},{"key":"4564_CR22","doi-asserted-by":"publisher","first-page":"8389","DOI":"10.1038\/s41598-024-57417-z","volume":"14","author":"K Cheng","year":"2024","unstructured":"Cheng K, Zhou Z, Chen Q, et al. CDK4\/6 inhibition sensitizes MEK inhibition by suppressing cell-cycle progression in pancreatic ductal adenocarcinoma. Sci Rep. 2024;14:8389. https:\/\/doi.org\/10.1038\/s41598-024-57417-z.","journal-title":"Sci Rep"},{"issue":"9","key":"4564_CR23","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/j.jval.2024.04.023","volume":"27","author":"M Mirza","year":"2024","unstructured":"Mirza M, Goerke L, Anderson A, et al. Cost-effectiveness of next-generation sequencing as a biomarker testing approach in oncology: a literature review. Value Health. 2024;27(9):1300\u20139. https:\/\/doi.org\/10.1016\/j.jval.2024.04.023.","journal-title":"Value Health"},{"issue":"9","key":"4564_CR24","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1016\/j.ccell.2024.08.002","volume":"42","author":"CA McIntyre","year":"2024","unstructured":"McIntyre CA, Grimont A, Park J, et al. Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer. Cancer Cell. 2024;42(9):1614-1629.e5. https:\/\/doi.org\/10.1016\/j.ccell.2024.08.002.","journal-title":"Cancer Cell"},{"issue":"5","key":"4564_CR25","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.pan.2025.06.013","volume":"25","author":"T Furukawa","year":"2025","unstructured":"Furukawa T, Fukada I, Hayashi N, et al. Clinical predictors of KRAS mutation detection in liquid biopsies for pancreatic ductal adenocarcinoma. Pancreatology. 2025;25(5):736\u201342. https:\/\/doi.org\/10.1016\/j.pan.2025.06.013.","journal-title":"Pancreatology"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04564-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04564-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04564-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:17:29Z","timestamp":1791940649000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04564-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":25,"alternative-id":["4564"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04564-6","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,13]]},"assertion":[{"value":"21 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that there are no conflicts of interest related to this work.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"University of Wisconsin-Madison Institutional Review Board approval and a waiver of informed consent were obtained from prior to data collection and analysis under protocols 2015\u20130052 and 2021\u20130975.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}